Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Is Moderna (MRNA) Quietly Recasting Its mRNA Platform From Pandemic Play to Broad Vaccine Franchise?
Biotech Stocks To Research - May 17th - Stock Observer
Salesforce (CRM) Valuation Check As New AI Deals And Air Force Contract Lift Market Interest
Best Biotech Stocks To Keep An Eye On - May 15th - Daily Political
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
Top Biotech Stocks To Consider - May 14th - Daily Political
Best Biotech Stocks To Keep An Eye On - May 15th - Stock Observer
Israel to offer non-mRNA coronavirus vaccine
BMJ Senior Editor: COVID vaccines more likely to put you in hospital than keep you out
Top Biotech Stocks To Consider - May 14th - Zolmax
Salesforce (CRM), Moderna Partner to Unify Global Operations via Agentforce Life Sciences
Want To Invest With Impact? Here Are 4 Options To Consider
3 Cash-Heavy Stocks with Warning Signs
Moderna's TIME Ranking And Combo Vaccine Approval Reshape Growth Question
Staged claims and Israeli hoaxes: Debunking viral conspiracy theories about hantavirus
Best Biotech Stocks To Consider - May 13th - Stock Observer
Still 'many steps to do' in creating a hantavirus vaccine, experts say
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
No cure, no approved vaccine, no antiviral: Why the Hantavirus threat is raising alarm again | Explained
Hantavirus fears put Moderna vaccine efforts in focus
Moderna Hantavirus Program Draws New Focus As Shares Outpace Targets
5 Insightful Analyst Questions From Moderna's Q1 Earnings Call
Health Care Down as Vaccine Bets Stall - Health Care Roundup | Morningstar
Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality.
New Moderna Short Target After Hantavirus Vaccine News
Here's how much Moderna's stock has rallied off renewed focus on hantavirus research | Morningstar
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges
Moderna shares jump as it reveals it has been researching vaccines against hantaviruses
Moderna Extends Rally After Two More Cruise Ship Passengers Test Positive For Hantavirus
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging. - AOL
Moderna stock surges 22% in 2 days as investors monitor hantavirus outbreak
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Premarket Winners: Moderna (MRNA), Intel (INTC), and Micron (MU) Rally on Monday
Moderna stock extends gains on hantavirus research
Hantavirus cases spark surge in pharma, biotech stocks - here's why
Best Medical Stocks To Watch Today - May 11th - Daily Political
Moderna (MRNA) Shares Surge 8% on Hantavirus Vaccine Research
Moderna shares jump 8% after U.S. national tests positive for hantavirus
Moderna (MRNA) Sees Gains Amid Market Uncertainty
Top Biotech Stocks To Consider - May 10th - Stock Observer
Personalis, Inc. (NASDAQ:PSNL) Q1 2026 Earnings Call Transcript
Moderna (MRNA) Gains Attention Amid Rising Virus Concerns
MRNA Stock Alert: Moderna Surges on Hantavirus Vaccine Hopes
Moderna (MRNA) Advances Hantavirus Vaccine Development Amid Renewed Interest
Moderna (MRNA) Stock Jumps 16% Following Positive Flu Vaccine Results and Wall Street Upgrades
Moderna (NASDAQ:MRNA) Trading 12.6% Higher - Should You Buy?
Moderna Flags Work on Hantavirus Vaccines Before Cruise Outbreak
Investors Buy Large Volume of Moderna Call Options (NASDAQ:MRNA) - Zolmax
Brookline Capital Markets Forecasts Moderna FY2026 Earnings - Stock Observer
Moderna, Vir among early 2026 top infectious disease gainers | BioWorld
Is Wall Street Bullish or Bearish on Moderna Stock?
Paranoia, turmoil and backlash: Inside the FDA under Marty Makary
Moderna Shareholders OK Directors, Executive Pay Votes and Ernst & Young as 2026 Auditor at AGM - Stock Observer
Has The Market Rerated Moderna (MRNA) Too Quickly After Its Recent Share Price Surge?
Biotech Stocks To Add to Your Watchlist - May 6th - Daily Political
Assessing Moderna (MRNA) Valuation After Strong Q1 Results And New EU Vaccine And Oncology Milestones
Brookline Capital Markets Weighs in on Moderna Q2 Earnings - Stock Observer
Sigma Planning Corp Purchases New Holdings in Moderna, Inc. $MRNA - Stock Observer
Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals | Markets Insider
MRNA Maintained by RBC Capital -- Price Target Raised to $38.00
Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock - Stock Observer
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
Moderna (NASDAQ:MRNA) Posts Quarterly Earnings Results - Stock Observer
Moderna (MRNA) Loss Of US$2.8b Keeps Bearish Narratives In Focus
Moderna Q1 Earnings Call Highlights - Stock Observer
Moderna, Inc. (NASDAQ:MRNA) Q1 2026 Earnings Call Transcript
Vanguard Group Inc. Purchases 399,487 Shares of Moderna, Inc. $MRNA - Stock Observer
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges
Q1 2026 Moderna Inc Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Receives $33.87 Average PT from Analysts - Daily Political
Moderna price target raised to $49 from $43 at Goldman Sachs | Markets Insider
Moderna (NASDAQ:MRNA) Announces Earnings Results
Health Care Up as Obesity-Drug Makers Regain Momentum - Health Care Roundup | Morningstar
S&P 500 and Nasdaq Surge to All-Time Highs Powered by Strong Earnings Reports
Is Moderna (MRNA) Overvalued After Q1 2026? EPS -$3.40 Miss vs -$2. ...
Moderna's Strong Vaccine Sales Outside US Far Surpass Estimates
Moderna Stock Rises After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.
Moderna (MRNA) Surges Nearly 8% as Q1 Revenue Crushes Wall Street Forecasts
Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.
Moderna, Inc Q1 Loss Climbs
MRNA shares: Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimates - The Economic Times
Moderna tops revenue estimates on stronger international COVID vaccine sales
Coronavirus - Articles | BioWorld
Moderna (MRNA) Prepares for Earnings Amid Revenue Challenges
Moderna loses key mRNA patent in European vaccine fight
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026
Best Biotech Stocks To Add to Your Watchlist - April 28th - Daily Political
CureVac targets Moderna with 10-patent suit over Spikevax
Moderna's H5N1 Vaccine Trial Draws Support As Valuation Stays Stretched
Biotech Visionary's Resilience Drives Platinum Fund Success
